Objective: Hepatitis C virus (HCV), being reported to be associated with a high prevalence of serological markers of autoimmunity in HCV-infected patients, and possibly sharing partial sequences in amino acid segments with thyroid tissue antigens, may be associated with interferon-a (IFN-a)-induced thyroid dysfunction in chronic hepatitis C patients. We conducted this study to clarify the issue. Design and Methods: One hundred and fifty chronic hepatitis C patients with normal baseline thyroid function were treated with IFN-a 2a, 2b and n1 (3-6 million Units three times weekly for 24 weeks). Pretreatment sera were tested for HCV genotype and HCV RNA levels. Serum thyrotropin, total thyroxine and free thyroxine index were performed every 4 weeks for 24 weeks followed by every 8 weeks for another 24 weeks. Results: Twenty-one (14.0%) patients developed early thyroid dysfunction (abnormal thyroid function during the first 3 months of therapy). Female gender, lower HCV RNA levels, IFN-a n1 and a lower IFN-a dose were significantly associated with early thyroid dysfunction. On multivariate analysis, gender, IFN-a preparation and HCV RNA levels were the significant factors associated with early thyroid dysfunction. Seven (4.7%) patients developed thyroid dysfunction during the second 3 months of IFN-a therapy. Taken together, 18.7% patients developed thyroid dysfunction. Female, mixed HCV genotype infection and lower HCV RNA levels were significantly associated with thyroid dysfunction. However, only gender remained significantly associated with IFN-a-induced thyroid dysfunction in multivariate analysis.
Introduction
Interferon-a (IFN-a) has been used for the treatment of various malignant diseases and chronic hepatitis C, with promising results (1, 2) . However, many sideeffects, including thyroid dysfunction, have been described. The frequency and clinical characteristics of thyroid dysfunction after IFN-a administration have been reported by many authors (3) (4) (5) (6) (7) (8) (9) (10) . Humoral factors, IFN-a preparation and dosage have been reported to be associated with thyroid dysfunction. Female gender and old age have been reported to be the risk factors for developing thyroid dysfunction in chronic hepatitis C patients treated with IFN-a, but others have disagreed (4, 8, 9, 11, 12) .
Chronic hepatitis C patients have been reported to show signs of autoimmunity, including autoantibodies and autoimmune diseases (13, 14) . It had been hypothesized that hepatitis C virus (HCV) might share partial sequences in a few amino acid segments with thyroid tissue antigens (15) . The HCV is a highly heterogenous virus. This quasi-species nature may contribute to different immune environments, and leads to different influences on thyroid dysfunction induced by IFN-a. In the present study, we have investigated the relationship between virologic factors and thyroid dysfunction in a prospective trial of IFN-a treatment for patients with chronic hepatitis C.
Subjects and methods
One hundred and seventy-two chronic hepatitis C patients (86 males and 86 females) received thyroid function tests including serum thyrotropin (TSH), total thyroxine (TT4), free thyroxine index (FT4I), antithyroglobulin (Tg-Ab) and anti-peroxidase (TPO-Ab) antibodies before this study. A total of 22 patients (5 males and 17 females) with thyroid abnormalities were excluded. Therefore, one hundred and fifty Taiwanese patients with normal baseline thyroid function were enrolled in the study. There were 81 males and 69 females, with ages ranging from 15 to 70 years (mean 45.2 Ϯ 11.9 years). The diagnosis of chronic viral hepatitis C was made when serum alanine aminotransferase (ALT) and aspartate aminotransferase were elevated for more than 6 months, they were HCV antibody positive, and the diagnosis was confirmed histopathologically by needle biopsy based on standard criteria (16) . The patients included 85 cases of chronic active hepatitis, 24 cases of chronic persistent hepatitis and 31 cases of liver cirrhosis. After giving informed consent, all patients with chronic hepatitis C were treated with lymphoblastoid IFN-a n1 (n ¼ 55), recombinant IFN-a 2a (n ¼ 29), or IFN-a 2b (n ¼ 66) given intramuscularly. There were three different regimens including: (a) low dose: 3 million Units (MU) three times a week for 24 weeks; (b) medium dose: 6 MU three times a week for 12 weeks followed by 3 MU three times a week for 12 weeks; and (c) high dose: 6 MU three times a week for 24 weeks. The presence of HCV RNA in the serum was assesed by nested reverse transcriptionpolymerase chain reaction (RT-PCR) every 3 months for 1 year. Complete responders were defined as patients showing normal ALT levels and clearance of HCV RNA by nested RT-PCR at the end of therapy and for 6 months after the cessation of therapy. All other patients were defined as non-responders.
Detection/quantification of serum HCV RNA and genotyping
Nested RT-PCR was performed to detect serum HCV RNA using 5 0 non coding region-specific primers (17) . HCV genotypes 1a, 1b, 2a, 2b and 3a were determined by amplification of the core region using genotypespecific primers described by Okamoto et al. (18) . Pretreatment serum HCV RNA levels were determined by using a branched-DNA assay (Quantiplex HCV RNA 2.0, Chiron, CA, USA), performed strictly according to the manufacturer's instructions.
Laboratory tests
Second-generation HCV antibody was detected with commercially available enzyme-linked immunosorbent assay kits (Abbott, North Chicago, IL, USA). Serum ALT level (normal upper limit of serum ALT ¼ 0:42 mkat/l) was measured on a multichannel autoanalyzer.
Thyroid function tests
Thyroid function tests, including serum TSH, TT4 and FT4I were performed by using commercial assay kits (Daiichi, LABSLTD, Japan). Tg-Ab and TPO-Ab were determined by using hemagglutinization kits (Fuji Rebio Co, Japan). Baseline thyroid function tests were performed before IFN therapy and then every 4 weeks for 24 weeks, followed by 8 weeks for another 24 weeks. The normal range of each assay was as follows: TSH, 0.4-5.0 mU/l; TT4, 58-155 nmol/l; FT4I, 1.55-4.0; Tg-Ab and TPO-Ab, <100. The definitions of thyroid dysfunction included: (a) hyperthyroidism, TSH < 0.1 mU/l accompanied by increased FT4I; (b) hypothyroidism, TSH >5.0 mU/l accompanied by decreased FT4I; (c) subclinical hyperthyroidism, TSH < 0.4 mU/l accompanied by normal FT4I; (d) subclinical hypothyroidism, TSH >5.0 mU/l accompanied by normal FT4I; and (e) destructive thyroiditis, hyperthyroidism or subclinical hyperthyroidism followed by hypothyroidism or subclinical hypothyroidism.
Statistical analyses
Frequency was compared between groups using the Chi-square test and group means using the t-test.
Stepwise logistic regression was used to analyze factors associated with thyroid dysfunction in chronic hepatitis C patients treated with IFN-a.
Results
Before being enrolled in the present study, all patients received thyroid function tests. One male (hypothyroidism) and four females (two with hypothyroidism, one with subclinical hypothyroidism and one with hyperthyroidism) had thyroid dysfunction. All these patients had Tg-Ab and/or TPO-Ab. Another four males and thirteen females with normal thyroid function had TgAb and/or TPO-Ab. The prevalence of thyroid abnormalities was 12.8% (males 5.8%, females 19.8%). A total of twenty-two patients with thyroid abnormalities were excluded. Fifty-three of one hundred and fifty (35.3%) chronic hepatitis C patients achieved complete response to IFN-a therapy. Table 1 summarizes the findings on patients with chronic hepatitis C who developed thyroid dysfunction induced by IFN-a. During the first 3 months of IFN-a therapy, twenty-one (14%) (three males and eighteen females) had thyroid dysfunction, including hyperthyroidism in five, subclinical hyperthyroidism in eight, subclinical hypothyroidism in five and destructive thyroiditis in three. Nine patients developed thyroid dysfunction in the 8th week of IFN-a therapy and twelve patients developed thyroid dysfunction in the 12th week of IFN-a therapy. We defined these patients as having early thyroid dysfunction. The abnormal thyroid function of patients 2, 3, 6, 9, 10, 14, 15, 19 and 21 returned to normal spontaneously during IFN-a therapy. The abnormal thyroid function of other patients returned to normal spontaneously within 24 weeks after cessation of IFN-a therapy, except for the persistent hyperthyroidism in patient 13 who received anti-thyroid drug therapy later. Unfortunately, this patient was diagnosed as having papillary thyroid carcinoma by cytology 6 months after cessation of IFN-a therapy and was treated by total thyroidectomy and 131 radioiodine therapy. During the second 3 months of IFN-a therapy, another seven patients (4.7%) (one male and six females) had thyroid dysfunction, including hyperthyroidism in two, subclinical hyperthyroidism in three, subclinical hypothyroidism in one and destructive thyroiditis in one. Two patients developed thyroid dysfunction in the 20th week of IFN-a therapy and five patients developed thyroid dysfunction in the 24th week of IFN-a therapy. All these patients were defined as having late thyroid dysfunction. These seven patients were all treated with 6 MU IFN-a given intramuscularly three times a week for 24 weeks. With the exception of patient 25 who developed persistent hyperthyroidism and received anti-thyroid drug therapy, all abnormal thyroid functions spontaneously returned to normal within 24 weeks after cessation of IFN-a therapy. Table 2 shows the characteristics of early thyroid dysfunction in chronic hepatitis C patients treated with IFN-a. In univariate analysis, the rate of thyroid dysfunction in females (18/69, 26.1%) appeared to be significantly higher than that in males (3/81, 3.7%) (P < 0.001). The patients treated with lymphoblastoid IFN-a n1 (13/55, 23.6%) had a significantly higher frequency of thyroid dysfunction than those treated with the other two recombinant IFN-a (8/95, 8.4%) (P < 0.05). The patients with early thyroid dysfunction induced by IFN-a had a markedly lower pretreatment serum HCV RNA level (P < 0.001) and received a significantly lower total dose of IFN-a in the first 3 months (P < 0.05) than those without early thyroid dysfunction. Further analysis, using stepwise logistic regression, revealed that female, lymphoblastoid IFN-a n1 and lower pretreatment HCV RNA levels were significant risk factors associated with early thyroid dysfunction induced by IFN-a. Table 3 lists the characteristics of all thyroid dysfunction induced by IFN-a in chronic hepatitis C patients.
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www.eje.org Presented as log (equivalent/ml). dysfunction (P < 0.01). Six of fourteen patients (42.6%) with an HCV mixed subtype infection developed thyroid dysfunction induced by IFN-a. The frequency was significantly higher than that of patients with a single subtype infection (22/136, 16 .2%) (P < 0.05). Further analysis, using stepwise logistic regression, revealed that only female gender remained as the significant risk factor associated with thyroid dysfunction induced by IFN-a therapy.
Discussion
The response rate of IFN-a therapy in chronic hepatitis C patients was 35.3% in the present study. It was as high as in those conducted by Toyoda et al. (19) and Kasahara et al. (20) with similar regimens. However, the response rate was much lower in the study conducted by Shiratori et al. (21) with the same dose and duration of IFN-a therapy. The regimen of IFN-a therapy is suggested to be one of the most important factors associated with HCV response. Many factors might contribute to the difference in response rate to similar regimens of IFN-a therapy, such as the distribution of HCV genotype, patient age and the duration of disease. Since genotype non-1b HCV was shown to have a better response to IFN therapy (22, 23) , the higher rate of HCV genotype non-1b infection in our patients might be responsible for the higher response rate to IFN therapy. However, further studies are necessary to find out any other important factors.
In the present study, 28 (18.7%) of 150 Taiwanese chronic hepatitis C patients developed thyroid dysfunction induced during IFN-a therapy in Taiwan. The incidence of thyroid dysfunction in previous individual studies has varied from 0% (24) to 34% (3). In our study, thyroid dysfunction included hyperthyroidism (4.7%), subclinical hyperthyroidism (7.3%), subclinical hypothyroidism (4.0%) and destructive thyroiditis (2.7%). These statistics are different from previous reports which revealed that the most common type of thyroid dysfunction induced by IFN was hypothyroidism (5, 8, 25) . The reason why we did not find hypothyroidism induced by IFN-a therapy in this study may be due to ethnic differences. Thyroid dysfunction induced by IFN-a therapy was usually reversible in most patients after the cessation of IFN-a therapy (26 of 28 patients, 92.9%) except for two patients who developed persistent hyperthyroidism and received anti-thyroid drug therapy. One patient was diagnosed as having thyroid papillary carcinoma, which might not be associated with IFN-a therapy.
To determine the relation of the virologic characteristics of HCV to IFN-a-induced thyroid dysfunction, HCV genotype and quantified serum HCV RNA levels before IFN-a therapy were determined. Whether by using univariate or multivariate analysis, pretreatment HCV RNA levels were significantly associated with thyroid dysfunction induced by IFN-a, especially early thyroid dysfunction. Chronic hepatitis C patients with lower HCV RNA levels have been shown to have higher cluster of differentiation (CD)4 counts and different immune environments (26, 27) , suggesting that a higher frequency of IFN-induced thyroid dysfunction may occur among this population. Another important finding in the present study was that the total frequency of IFN-ainduced thyroid dysfunction was higher in patients with mixed HCV subtype infection than in those with single HCV subtype infection. HCV, exiting high genomic variation, could be divided into different genotypes. The mixed subtype infection has been reported to be with a different immune environment from the single type infection (28) . The hypothesis has emerged that HCV may infect the thyroid tissue and lead to a change in the structure and immune reaction of the thyroid gland. However, the HCV genotype-specific difference in IFN-ainduced thyroid dysfunction did not exist after controlling the confounding factors by using multivariate analysis in the present study. However, the association of HCV genotypes with IFN-a-induced thyroid dysfunction might be masked by strong factors, such as female gender in the present study. Further larger scale studies are needed to clarify the relation between HCV genotypes and IFN-a-induced thyroid dysfunction.
It has been reported that HCV might share a partial sequence in a few amino acid segments with thyroid tissue antigens (15 D00944) . The amino acid sequence 647-653 of thyroglobulin shared six amino acids with the amino acid sequence 3047-3053 of HCV type 1. The amino acid sequence 1047-1054 of thyroglobulin shared six amino acids with the amino acid sequence 2647-2654 of HCV type 2. The amino acid sequence 471-476 of microsome and the amino acid sequence 471-476 of HCV type 3 were the same. Since HCV shared a partial sequence in a few amino acid segments with thyroglobulin and microsome, chronic hepatitis C patients might be more susceptible to autoimmune thyroid diseases.
The thyroid dysfunction induced by IFN-a may become apparent at any time during IFN-a therapy. The time of thyroid dysfunction induced by IFN-a seemed to be separated into two different parts, including early thyroid dysfunction (8-12 weeks after IFN-a therapy) and late thyroid dysfunction (20-24 weeks after IFN-a therapy). Previous studies have reported that thyroid dysfunction could develop from a few weeks to a few months after the start of IFN-a therapy and after the cessation of IFN-a therapy (6, 7, 9, 29) . The mechanism by which IFN-a therapy induced thyroid dysfunction is unclear. IFN-a may act as an immunomodulatory agent leading to thyroid dysfunction in susceptible patients (6, 8, (30) (31) (32) . In addition, IFN could directly affect both thyroid hormone synthesis and secretion in vitro (33) . In the present study, lymphoblastoid IFN-a n1 was found to induce a higher frequency of early thyroid dysfunction than recombinant IFN-a. One previous study has revealed that trace amounts of contaminated IFN-g in natural IFN-a were believed to be a cause of INFinduced autoimmunity (4) . Differences in the structures of lymphoblastoid IFN-a n1 and recombinant IFN-a may be another possibility. All seven patients who developed late thyroid dysfunction induced by IFN-a received a high dose of IFN-a (6 MU three times a week for 24 weeks). These findings suggest that a cumulative dose of IFN might also play a contributing role. Further study is needed to clarify the dose-dependent thyroid dysfunction.
Thyroid dysfunction was not associated with the response of chronic hepatitis C to IFN-a therapy in the present study; in contrast a positive relationship between the appearance of thyroid dysfunction and the response to IFN-a therapy was observed in previous studies (7, 34, 35) . However, all those previous studies did not evaluate the pretreatment serum HCV RNA levels. The pretreatment HCV RNA level is one of the factors influencing the outcome of IFN-a treatment (19, 36, 37) and may, in fact, be the single most important determinant. Thus, the viral load-related thyroid dysfunction might mimic the relation between the response of chronic hepatitis C to IFN-a therapy and thyroid dysfunction.
In conclusion, 18.7% of chronic hepatitis C patients developed thyroid dysfunction during IFN therapy in the present study. Most of the IFN-a-induced thyroid dysfunction was reversible (92.9%). Gender (female) is a strong risk factor for thyroid dysfunction induced by IFN-a. However, the virologic features of HCV may be associated with thyroid dysfunction in chronic hepatitis C patients treated with IFN-a.
